Importantly, since concerns about urinary tract infection risk are expected to mitigate the administration of SGLT2-i, especially in kidney transplant recipients with recurrent urinary tract infection episodes, high immunosuppression status, or altered urinary tract anatomy, large-scale studies are needed to define the patient subpopulation in which SGTL2-is would provide an optimal cost–benefit ratio. This evidence concerns the gene SLC5A2 and urinary tract infection.